Search
for
Sort by
Research 151–180 of 1000+
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Systemic Therapies for Scarring and Non-scarring Alopecia
- Alopecia Areata
- Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
- Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
- Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- JAK inhibitors for alopecia areata: a systematic review and meta‐analysis
- A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo
- Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience
- USE OF UPADACITINIB IN 2 CASES OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- A case of dupilumab-induced psoriatic alopecia
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Excellent response to tofacitinib treatment in a patient with alopecia universalis
- 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- 1359 Hair growth is induced by blockade of macrophage-derived oncostatin M and downstream JAK-STAT5 signaling in hair follicle stem cells
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Design and Characterization of Baricitinib Incorporated PLA 3D Printed Pills by Fused Deposition Modeling: An Oral Pill for Treating Alopecia Areata